Gritstone files for bankruptcy, says it could forge a transaction as early as...
Gritstone bio filed for Chapter 11 bankruptcy on Thursday morning in a bid to keep itself afloat as it seeks a buyer or other transaction to continue running R&D of its cancer and infectious...
View ArticleClik here to view.
#CPHI24: Clients add pressure to CDMOs to source raw materials outside of...
MILAN — CDMOs are increasingly fielding inquiries from biopharma clients on how reliant they are on China for their raw materials, off the back of industry anxiety on how the Biosecure Act would play...
View ArticleExclusive: Reema Health raises $7.6M to reach people on Medicaid
A startup that helps community workers guide Medicaid members to the care they need just raised a new round of funding. People on government-run Medicaid insurance for low-income households can often...
View ArticleSuki nabs $70M Series D to arm doctors with AI tools
Suki, a startup that provides AI tools to help healthcare providers with documentation, billing and other administrative work, raised $70 million in a Series D funding round. The round was led by...
View ArticleStarboard launches first salvo in Pfizer fight, alleging ex-CEO, CFO were...
The activist investor targeting Pfizer claims that the company’s former CEO and CFO, who were previously working with the investor, were pressured to flip and side with the company. In a public letter...
View ArticleOno’s ADC deal; Leo Pharma to conduct layoffs
Plus, news about Booster Therapeutics, Century Therapeutics and Holobiome: Ono Pharmaceutical’s ADC deal: The Japanese drugmaker will pay up to $700 million to LigaChem Biosciences to develop, produce...
View ArticleAI biotechs Recursion and Exscientia first held deal talks in 2022
When Recursion Pharmaceuticals and Exscientia announced plans to merge in August, it marked the first major consolidation in the early AI-driven biotech field. The all-stock deal, touted as an alliance...
View ArticleBehind the scenes of how ex-Pfizer CEO and CFO joined activist Starboard
The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from his former CFO Frank D’Amelio. While there was no content in the email, the...
View ArticleBaxter plots recovery after Hurricane Helene, MilliporeSigma’s €290M facility
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Baxter said that it is increasing manufacturing at its sites outside...
View ArticleSen. Warren urges FTC to ‘carefully scrutinize’ Novo-Catalent deal over...
Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the deal could give Novo Nordisk “unprecedented visibility” into its competitors’...
View ArticleImmatics heads to Phase 3 with melanoma cell therapy, seeks to raise $150M
Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an early-stage trial, and the company plans to start a pivotal study by the end...
View ArticleEli Lilly inks another obesity pact, doubling down on small Swiss partner
Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup to work on dual amylin calcitonin receptor agonists for obesity and other...
View ArticleSeven patients diagnosed with blood cancer after Skysona treatment, new data...
Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood cancer months or years after treatment, according to data published on Wednesday...
View ArticleClik here to view.
FDA approves Roche's new treatment for subset of breast cancer patients
The FDA has approved Roche’s inavolisib plus Pfizer’s Ibrance and fulvestrant in a subtype of breast cancer over a month before the target action date, the agency announced Thursday. The treatment,...
View ArticleFDA adcomm supports first potential drug for ultra-rare, fatal Barth syndrome
Heart-breaking anecdotes from the patients, parents and doctors of children with the ultra-rare and fatal Barth syndrome won over an FDA advisory committee on Thursday, likely setting up a tough...
View ArticleSanofi discontinues Denali-partnered MS trial after Phase 2 failure
Sanofi is ending a Phase 2 clinical trial that’s testing a drug from Denali for multiple sclerosis, ending the development plan. Denali said in an SEC filing Thursday that Sanofi notified the company...
View ArticleBiotech startups Upstream, CAMP4 price Friday IPOs
Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in what appears to be a recovery for startups trying to raise capital on the...
View ArticleClik here to view.
Lilly follows the trend of new AI hires; Pfizer fills key UK position as...
Thomas Fuchs → Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief AI officer on Oct. 21 and comes from the Icahn School of...
View ArticleExclusive: PhRMA attacks federal government's response to rebate model for 340B
The pharma industry’s DC-based lobbying group urged the federal government on Friday to get on board with alternative models for 340B drug price discounts. In a letter to the Health Resources and...
View ArticleClik here to view.
VC firm targets $35M second fund to back startups led by scientists
A small venture capital firm that backs up-and-coming scientists plans to raise a $35 million second fund, three years after coming onto the scene. SciFounders, based in the San Francisco Bay Area, is...
View Article